Innovent Biologics (HKEX: 01801) announced that two Phase 3 clinical studies of its diabetes drug mazdutide were published in Nature ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE